As Chief Business Officer at Impel Neuropharma, Ms. Lubman is responsible for Business and Corporate Development activities and strategy, including aspects of Investor Relations. Impel NeuroPharma, Inc. is a private Seattle based company developing intranasal drug treatments for central nervous system (CNS) disorders. They have developed a novel drug delivery platform, the POD™ technology, that administers medicine deep into the nasal cavity. The POD™ technology achieves consistent and predictable biodistribution of the medicine to improve clinical outcomes for patients.

Ms. Lubman brings to Impel nearly 20 years of biopharmaceutical industry experience, including global partnering, asset sourcing and acquisition, financial structuring and leading early-stage company operations, fundraising and board governance.

Prior to joining Impel, she served as the Vice President of External Science & Innovation at Allergan, where she was responsible for strategic expansion of the company’s pipeline in a variety of disease areas, including Alzheimer’s disease, Parkinson’s disease and autism. Prior to joining Allergan, Ellen served in financial, strategic, commercial and corporate development executive positions at Kadmon Pharmaceuticals, Bristol-Myers Squibb, Celtic Pharma Management, L.P., Robertson Stephens Investment Bank and Abbott Labs.

She has her MBA from Stanford Graduate School of Business with a focus on Global Management and her B.A. in Biology from Rutgers College. Ellen also serves on the Board of Directors of GeneCentric Therapeutics and is on the Scientific Advisory Board of the Daedalus Innovation Fund of Weill-Cornell.